Lactic acid bacteria contain components

Abstract

To provide novel effects and uses of lactic acid bacteria.SOLUTION: The present invention provides an anti-obesity composition containing Lactiplantibacillus plantarum S25 strain (accession number: NITE ABP-03571).SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to a composition containing lactic acid bacteria and its uses, etc. The content of all documents described in this specification is incorporated herein by reference.

Background Art

[0002] It has been studied that various effects are exerted by lactic acid bacteria fermentation products. For example, it is known that effects such as improvement of the intestinal barrier (Patent Document 1) or improvement of the skin (Patent Document 2) are exerted, and useful lactic acid bacteria are being searched for.

Prior Art Documents

Patent Documents

[0003]

Patent Document Ⅰ

Patent Document Ⅱ

Summary of the Invention

Problems to be Solved by the Invention

[0004] The inventors of the present invention searched for new effects and uses of lactic acid bacteria.

[0005] The inventors of the present invention Genus lactic acid bacteria (Lactiplantibacillu s) found that visceral fat can be reduced by ingesting S25 strain (Accession No.: NITE ABP-03571), and further improvements were made.

[0006] The present disclosure includes, for example, the subject matter described in the following items. [[ID=…]] Item 1. Lactiplantibacillu Genus lactic acid bacteria (Lactiplantibacillu s) A composition for anti-obesity containing S25 strain (Accession No.: NITE ABP-03571). Section 2. The composition according to item 1, for use in at least one of the following uses selected from the group consisting of weight reduction, visceral fat reduction, fatty liver risk reduction, liver function enzyme level improvement, blood cholesterol concentration reduction, and blood uric acid level reduction. Section 3. The composition described in item 1 or 2, which is an oral composition. Section 4. A composition according to any one of items 1 to 3, which is a food or beverage composition or a pharmaceutical composition. [Effects of the Invention]

[0007] Lactiplantibacillus Genus lactic acid bacteria (Lactiplantibacillus s) An anti-obesity composition containing the S25 strain is provided. [Brief explanation of the drawing]

[0008] [Figure 1A] This graph shows the time course of body weight changes in mice orally administered a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * and + indicate p<0.05, ** indicates p<0.01, and *** indicates p<0.001. [Figure 1B] The data shows the body weight at dissection of mice that were orally fed a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * indicates p<0.05, and *** indicates p<0.001. [Figure 2A] This table shows the time-dependent weight gain of mice orally fed either a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * and + indicate p<0.05, ** and ++ indicate p<0.01, and *** indicates p<0.001. [Figure 2B]This table shows the weight gain from the start of administration to dissection in mice orally fed either a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * indicates p<0.05, and *** indicates p<0.001. [Figure 3A] This table shows the perigenital fat mass (g / 100g body weight) of mice orally fed a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). ** indicates p<0.01, and *** indicates p<0.001. [Figure 3B] This table shows the perirenal and posterior abdominal fat mass (g / 100g body weight) of mice orally fed a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * indicates p<0.05, and *** indicates p<0.001. [Figure 3C] This table shows the mesenteric fat content (g / 100g body weight) of mice orally fed a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * indicates p<0.05, and *** indicates p<0.001. [Figure 3D] This table shows the visceral fat mass (total of perigenital fat, perirenal and posterior abdominal wall fat, and mesenteric fat) (g / 100g body weight) of mice orally fed a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). ** indicates p<0.01, and *** indicates p<0.001. [Figure 4A] This table shows the blood alanine aminotransferase (ALT) concentration (IU / L) of mice orally administered a normal diet (Control), a high-fat diet (HFD), or a high-fat diet and lactic acid bacteria (HFD+S25). * indicates p<0.05, and ** indicates p<0.01. [Figure 4B]Shows the total cholesterol (T-CHO) concentration (mg / dL) in the blood of mice orally administered normal feed (Control), high-fat diet feed (HFD), or high-fat diet feed and lactic acid bacteria (HFD+S25). Note that * indicates p<0.05 and ** indicates p<0.01, respectively. [Figure 4C] Shows the blood uric acid level (nmol / mL) of mice orally administered normal feed (Control), high-fat diet feed (HFD), or high-fat diet feed and lactic acid bacteria (HFD+S25). Note that * indicates p<0.05. [Figure 5] Shows the amount of acetic acid (μmol / gl) in the cecal contents of mice orally administered normal feed (Control), high-fat diet feed (HFD), or high-fat diet feed and lactic acid bacteria (HFD+S25). Note that *** indicates p<0.001.

Mode for Carrying Out the Invention

[0009] Hereinafter, each embodiment included in the present disclosure will be described in more detail. The composition included in the present disclosure is an oral composition containing lactic acid bacteria. In this specification, the composition may be referred to as "the composition of the present disclosure".

[0010] The lactic acid bacteria included in the present disclosure are Lactiplantibacillus Genus lactic acid bacteria (Lactiplantibacillu s) S25 strain (Accession No.: NITE ABP-03571). Lactiplantibacillus Genus lactic acid bacteria The S25 strain was received on December 15, 2021, at the Patent Microorganisms Depositary, National Institute of Technology and Evaluation (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan) under the accession number NITE ABP-03571.

[0011] The lactic acid bacteria of the present disclosure are plant-derived lactic acid bacteria isolated from suzukake, which is a Kyoto pickled vegetable.

[0012] The lactic acid bacteria content in the composition of this disclosure is not particularly limited, but is preferably about 0.1 to 100% by mass, more preferably about 1 to 99% by mass, 2 to 90% by mass, or 5 to 50% by mass.

[0013] In the compositions of this disclosure, the lactic acid bacteria may be live or dead. Of these, dead bacteria are preferred.

[0014] In the compositions of this disclosure, the lactic acid bacteria may or may not undergo treatments such as crushing, heating, drying (freeze-drying, vacuum drying, spray drying, etc.), freezing, lysis, or extraction.

[0015] The compositions of this disclosure contain the lactic acid bacteria described above and may further contain other components. Examples of such other components include pharmacologically or food-hygiene-acceptable bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, antioxidants, preservatives, coatings, colorants, etc. These components may be used individually or in combination of two or more.

[0016] The compositions of the present invention are not particularly limited, but may include, for example, oral compositions.

[0017] The composition of the present invention may be a pharmaceutical composition or a food or beverage composition. If it is a food or beverage composition, it may be, for example, a processed food, a beverage, a health food (nutrient functional food, food for specified health uses, etc.), a supplement, or a food for the sick (hospital food, sick person's food, or nursing care food, etc.).

[0018] The compositions of this disclosure can be prepared by conventional methods by combining the lactic acid bacteria described above with other components as needed.

[0019] The compositions of this disclosure may have a preventive effect against lifestyle-related diseases. More specifically, the compositions of this disclosure may have a weight reduction effect, a visceral fat reduction effect, a body fat reduction effect, a fatty liver risk reduction effect, an improvement in liver function enzyme levels, a blood cholesterol concentration (more specifically, total blood cholesterol concentration) reduction effect, and / or a blood uric acid level reduction effect. For this reason, the compositions of this disclosure are preferably used for anti-obesity purposes, weight reduction, visceral fat reduction, body fat reduction, fatty liver risk reduction, improvement in liver function enzyme levels, blood cholesterol concentration reduction, and / or blood uric acid level reduction. Examples of liver function enzymes include blood alanine aminotransferase (ALT, also known as GPT).

[0020] In this specification, "fatty liver risk" refers to the degree of risk of developing fatty liver disease. Blood ALT concentration is a value used as an indicator of liver function and can be used to assess fatty liver risk. Furthermore, since blood ALT concentration increases in fatty liver disease, it is possible that blood ALT concentration will increase as fat accumulation, such as visceral fat, increases. For this reason, blood ALT concentration can also be used as an indicator of visceral fat volume.

[0021] It is known that purine metabolism is enhanced in the gut bacteria of obese mice, resulting in elevated blood uric acid levels (mBio, 2021 Jun 29;12(3)). Therefore, blood uric acid levels can be used as an indicator of obesity.

[0022] Acetic acid is known to activate GPR43, a short-chain fatty acid receptor, and suppress fat accumulation. Therefore, the amount of acetic acid in cecal contents can be used as an indicator of visceral fat volume. The composition of this disclosure can also be used to promote acetic acid production by intestinal bacteria.

[0023] Examples of animals that may ingest the compositions of this disclosure include humans and other mammals (e.g., rats, mice, rabbits, cattle, pigs, dogs, cats, sheep, monkeys, etc.). Examples of people who may be obese include: obese individuals or those suspected of being obese (e.g., men with a waist circumference of 85 cm or more, women with a waist circumference of 90 cm or more, etc.), or individuals with a BMI in the upper-normal range (23-25); individuals with a high body fat percentage (e.g., men with a body fat percentage of 20% or more, women with a body fat percentage of 30% or more, etc.); and individuals with a large amount of visceral fat (e.g., a visceral fat area of ​​100 cm²). 2 The following are examples of people who may be at risk of obesity: those who are concerned about abdominal fat or waist size; those with high liver enzyme levels (e.g., blood alanine aminotransferase, etc.) (e.g., blood alanine aminotransferase level of 31 IU / L or higher); those with high blood total cholesterol levels; those with high blood uric acid levels; those with unbalanced diets (e.g., those who have gained more than 3 kg in a year, those who have gained more than 10 kg since the age of 20, those who eat dinner within 2 hours of going to bed more than 3 times a week, those who snack after dinner more than 3 times a week, etc.) and those with an unbalanced gut environment (e.g., those who have a diet high in fat, etc.). Furthermore, even if these symptoms are not present, it can be used preventively for anti-obesity purposes.

[0024] The amount of lactic acid bacteria ingested is not particularly limited, but for example, 1 to 100 billion per day (especially per day for adults) is preferred, and 1 to 10 billion per day is more preferred. The amount of lactic acid bacteria contained in the composition disclosed herein can also be set based on the daily intake of lactic acid bacteria. Typically, 1.0 × 10 per gram of dead lactic acid bacteria powder. 11 ~1.0~10 13 Since it contains approximately [number] lactic acid bacteria, for example, the composition can be prepared by setting the amount of dead lactic acid bacteria powder in the composition to match the above-mentioned daily intake of lactic acid bacteria, using this value as a reference. Alternatively, the amount of lactic acid bacteria contained in the composition can be set to, for example, 1 / 2 or 1 / 3 of the above-mentioned daily intake of lactic acid bacteria, and the composition can be consumed several times a day (2 or 3 times).

[0025] In this specification, the term "comprising" includes both "consisting essentially of" and "consisting of." Furthermore, this disclosure encompasses all combinations of the constituent elements described herein.

[0026] Furthermore, the various characteristics (properties, structure, function, etc.) described in each embodiment of this disclosure above may be combined in any way to identify the subject matter covered by this disclosure. In other words, this disclosure covers all subject matter consisting of any combination of the combinable characteristics described herein. [Examples]

[0027] The embodiments of this disclosure will be described in more detail below with examples, but the embodiments of this disclosure are not limited to the examples below.

[0028] Animals used Three-week-old male mice (C57BL / 6J (SPF)) were purchased from Charles River Japan Co., Ltd. and used in the experiment. The period from arrival to group division was considered the acclimatization period. The quarantine period was set to 7 days, with the arrival day being day 0. During the quarantine and acclimatization period and the test period for group A, D12450J (normal feed (feed 1), RESEARCH DIETS, INC. lot number: 20080303) was placed on the cage lid, and during the test periods for groups B and C, D12492 (high-fat diet (HFD; feed 2), RESEARCH DIETS, INC. lot numbers: 20090202, 20110303) was placed, and the mice were allowed to feed freely except during fasting periods. Drinking water was provided freely throughout the test period using a polysulfone water dispenser (stainless steel tip).

[0029] Grouping Based on body weight measured on the last day of the quarantine and acclimatization period, the animals were divided into groups using a stratified continuous randomization method according to the table below.

[0030] [Table 1]

[0031] The test substance was Lactiplantibacillus. Genus lactic acid bacteria S25 strain (receipt number: NITE ABP-03571) (dead bacteria) was used. In the table above, the dose is shown in mg / animal, but if shown in bacterial count, 10 dead bacteria hundred million This corresponds to the amount ingested per person per day. The test substance was administered via a tube using distilled water. Mice in the group not receiving the test substance were administered distilled water via tube. The administration period was 77 days. Figures 1A and 1B show the changes in body weight over time during the administration period and the body weight at dissection. Figures 2A and 2B show the changes in the amount of body weight gain over time during the administration period and the amount of body weight gain from the start of administration to dissection.

[0032] As shown in Figures 1A, B and 2A, B, Lactiplantibacillus Genus lactic acid bacteria Weight loss was observed in the group administered with the S25 strain.

[0033] After the administration period, the subjects were fasted overnight, anesthetized, and then dissected. Visceral fat (total of perigenital fat, perirenal and posterior abdominal wall fat, and mesenteric fat) was collected, its weight was measured, and the value per 100g of body weight (g / body weight 100g) was calculated. The results are shown in Figures 3A-D. In addition, the alanine aminotransferase (ALT) concentration (IU / L), total cholesterol (T-CHO) concentration (mg / dL), and blood uric acid level (nmol / mL) were measured in the collected blood. The results are shown in Figures 4A-C.

[0034] As shown in Figures 3A-D, Lactiplantibacillus Genus lactic acid bacteria In the group administered with strain S25, a reduction in perigenital fat, perirenal and posterior abdominal wall fat, mesenteric fat, and visceral fat was observed. Furthermore, as shown in Figures 4A-C, lactiprantibacillus Genus lactic acid bacteria In the group administered with the S25 strain, reductions in serum ALT concentration, serum T-CHO concentration, and serum uric acid levels were observed.

[0035] In addition, the amount of acetic acid (μmol / gl) in the cecal contents was measured. The results are shown in Figure 5.

[0036] As shown in Figure 5, Lactiplantibacillus Genus lactic acid bacteria In the group administered with the S25 strain, an increase in the amount of acetic acid in the cecal contents was observed.

[0037] Furthermore, Lactiplantibacillus was found in a suspension of feces collected from six subjects. Genus lactic acid bacteria When strain S25 (receipt number: NITE ABP-03571) (dead bacteria) was added and cultured, an increase in the number of Faecalibacterium and Bifidobacterium species, as well as an increase in the concentrations of acetic acid and butyric acid, were observed.

Claims

1. An anti-obesity composition containing Lactiplantibacillus strain S25 (receipt number: NITE ABP-03571).

2. A composition containing Lactiplantibacillus strain S25 (receipt number: NITE ABP-03571) for use in at least one of the following applications selected from the group consisting of weight reduction, visceral fat reduction, fatty liver risk reduction, liver function enzyme level improvement, blood cholesterol level reduction, and blood uric acid level reduction.

3. The composition according to claim 1 or 2, which is an oral composition.

4. The composition according to any one of claims 1 to 3, which is a food or beverage composition or a pharmaceutical composition.

Images